Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) is now available.
Lumos Diagnostics Holdings Ltd. has applied for quotation on the ASX of 4,495,817 new ordinary fully paid shares, dated 4 March 2026. The new securities arise from the exercise or conversion of existing options or other convertible securities, modestly expanding the company’s listed share base and potentially enhancing its liquidity in the market.
This additional quotation reflects ongoing capital structuring activities and signals continued engagement with equity markets to support Lumos Diagnostics’ corporate objectives. For existing shareholders and potential investors, the incremental increase in quoted securities may influence trading dynamics, including turnover and market depth for the LDX stock.
The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.25 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics Holdings Ltd. is a medical diagnostics company listed on the ASX under the code LDX. The company issues ordinary fully paid shares and operates within the healthcare and diagnostics sector, focusing on capital market activities to support its operations and growth.
Average Trading Volume: 3,861,751
Technical Sentiment Signal: Buy
Current Market Cap: A$234M
For a thorough assessment of LDX stock, go to TipRanks’ Stock Analysis page.